Companies sometimes raise big venture capital rounds to invest in equipment, people, and other tools for growth. Other times they do it to provide the business a cash cushion. And sometimes it’s about giving potential customers and partners more confidence in the fledgling company.
For Ginkgo Bioworks, its latest venture funding round is about all of the above, says CEO and co-founder Jason Kelly. The Boston-based synthetic biology company today announced a $275 million Series D funding round, which the nine-year-old firm says brings its total venture capital haul to $429 million. Ginkgo is now valued at more than $1 billion... Read more »
UNDERWRITERS AND PARTNERS